SOPHiA Genetics (NASDAQ: SOPH) has priced an underwritten public offering of 10,526,000 ordinary shares at $4.75 per share, with gross proceeds expected to reach approximately $50 million before underwriting discounts, commissions, and other expenses, according to a press release.

All shares in the offering will be sold by the company. SOPHiA Genetics has also granted underwriters a 30-day option to purchase up to 1,578,900 additional ordinary shares at the public offering price, less underwriting discounts and commissions.

The offering is expected to close on June 18, 2026, subject to customary closing conditions.

TD Cowen is acting as lead book-running manager for the offering. Guggenheim Securities is serving as book-running manager, while BTIG and Craig-Hallum are acting as lead managers.

The offering is being made pursuant to a registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission, which was declared effective on August 15, 2025.